NEW YORK (GenomeWeb) – Intrexon has entered into a definitive agreement to buy bovine genetics firm Trans Ova Genetics for up to $110 million. Shareholders will receive $60 million in upfront cash, $30 million in Intrexon stock, and up to $20 million in deferred payments. Trans Ova will become a wholly owned subsidiary of Intrexon upon completion of the transaction, which is expected in the third quarter, and will be led by David Faber, currently Trans Ova's president, and his management team.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.